Evogene (NASDAQ:EVGN) Shares Pass Below Two Hundred Day Moving Average – Here’s What Happened

Evogene Ltd. (NASDAQ:EVGN)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.50 and traded as low as $1.43. Evogene shares last traded at $1.45, with a volume of 22,169 shares.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Evogene in a report on Thursday. They set a “sell” rating on the stock.

Evogene Stock Down 1.7 %

The stock’s 50 day moving average is $1.58 and its two-hundred day moving average is $2.50. The company has a market capitalization of $7.75 million, a PE ratio of -0.32 and a beta of 1.29.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by institutional investors and hedge funds.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.